Navigation Links
Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
Date:8/18/2009

Zurich, Switzerland, August 18, 2009 / b3c newswire / -Neurimmune Therapeutics AG today announced that, following the successful completion of key research milestones, its lead human therapeutic antibody for Alzheimers disease has advanced into preclinical development, triggering milestone payments of an undisclosed amount from Biogen Idec (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimers disease in November 2007. The alliance focuses on the development of antibodies that bind to amyloid beta (Abeta), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimers patients.

Neurimmunes unique Reverse Translational Medicine (RTM) technology platform combined with in-depth expertise in neuroscience played a critical role in moving the program forward. The fact that we could reach all preclinical milestones in such a short period of time shows that our RTM technology can significantly accelerate the transition from discovery to development of human monoclonal antibodies, said Jan Grimm, Chief Scientific Officer of Neurimmune Therapeutics.

The rapid advancement into preclinical development demonstrates the progress and productivity of our collaboration with Biogen Idec we are very happy to work with a partner that has such extensive and valuable experience in the development of biopharmaceuticals. The significant milestone payments also provide Neurimmune with additional financial stability to support the sustainable future development of our company, said Michael Salzmann, COO and General Manager of Neurimmune Therapeutics.

Biogen Idec is globally recognized as a leader in the development of innovative therapies for neurologic diseases, and this program is an important entry into Alzheimers disease for us, said Kenneth Rhodes, PhD, Vice President, Discovery
'/>"/>
b3c newswire

0

GOOD

Page: 1 2 3

Related biology news :

1. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
2. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
3. NIH announces new program to develop therapeutics for rare and neglected diseases
4. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
5. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
6. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
7. A novel target for therapeutics against Staph infection
8. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
9. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
10. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
11. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...cientists are revealing the genetic instructions i...n, or maize, has one of the most complex sequences...n-Madison genomicist David Schwartz, who was one o...nal Science . , "The maize genome is a true maz...ve troubled would-be sequencers for years," says S...
(Date:11/19/2009)..., NY A four-year, multi-institutional effort co-l...cientists culminated today in publication of a lan...vealing in unprecedented detail the DNA sequence o...monly called by North American consumers, is one o...aluable agricultural crop grown in the United Stat...
(Date:11/19/2009)... of researchers at Louisiana Tech University has f... as a natural herbicide against giant salvinia. ,... weed that can block all sunlight penetration into...er ideal conditions, it,s been reported that giant... Dr. H. Lynn Walker, professor of biological scien...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Microorganism may provide key to combating giant salvinia throughout Louisiana 2Roxane Laboratories Inc Announces the Launch of Perindopril Erbumine Tablets 61100 1Roxane Laboratories Inc Announces the Launch of Perindopril Erbumine Tablets 61100 2Cardiogenesis Reports Third Quarter 2009 Results 6149 1Cardiogenesis Reports Third Quarter 2009 Results 6149 2Cardiogenesis Reports Third Quarter 2009 Results 6149 3Cardiogenesis Reports Third Quarter 2009 Results 6149 4Cardiogenesis Reports Third Quarter 2009 Results 6149 5Cardiogenesis Reports Third Quarter 2009 Results 6149 6Cardiogenesis Reports Third Quarter 2009 Results 6149 7Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17 6146 1
...pain than people who aren,t obese, a new study sug... study had osteoarthritis of the knee, a disease t...ees. , Participants were given a mild electrical ...ain reflex. The stimulus was given before and afte... skills training session that included a progressi...
...the marine food chain, albatrosses accumulate toxi...heir bodies. A new study has found dramatic differ...lated albatross species that forage in different a...that levels of PCBs and DDT have increased in both...s in contaminant levels between black-footed and L...
...ded by an infectious agent, for example, the body ...efeat the intruder. But when the biochemical proce...r chronically turned on, inflammation can lead to ...is reason, scientists are closely studying the lin...on, while others are investigating anti-inflammato...
Other Biology News:Obese people are more sensitive to pain, suggests study 2Obese people are more sensitive to pain, suggests study 3Albatross study shows regional differences in ocean contamination 2Albatross study shows regional differences in ocean contamination 3Inflammation and drugs to control this activity studied in a variety of tumors sites 2Inflammation and drugs to control this activity studied in a variety of tumors sites 3Inflammation and drugs to control this activity studied in a variety of tumors sites 4Inflammation and drugs to control this activity studied in a variety of tumors sites 5Inflammation and drugs to control this activity studied in a variety of tumors sites 6Inflammation and drugs to control this activity studied in a variety of tumors sites 7Inflammation and drugs to control this activity studied in a variety of tumors sites 8Inflammation and drugs to control this activity studied in a variety of tumors sites 9
(Date:11/20/2009)... November 20 Karolinska Developmen...Fund (EIF) has entered into a,co-investment agreem...be,managed by Karolinska Development and used to i...armaceutical and medical technology companies. EIF...tment fund. The agreement,represents EIF,s largest...
(Date:11/19/2009)... be able to charge their cell phones and other per...ent discovery made by UC San Diego engineers could...t could do just this. , In recent research, pub...daru, a professor in the UCSD Department of Mechan...e student Mark Hoefer, have found that artificiall...
(Date:11/19/2009)...DA, Md., Nov. 19 Spherix...otechnology for diabetes therapy, and a provider o...food, supplement, biotechnology and pharmaceutical...ly reported $6.3 million registered direct placeme...of its common stock and warrants to purchase up to...
(Date:11/19/2009)...rmany, November 19 MONITORING FORC...16th, 2009 Flibanserin in the,indication treatment...,s,disease for orphan drug status designation with...duced dyskinesia is a complication of the mainstay...urden to some of those,affected, since it may be d...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Nanotube defects equal better energy and storage systems 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...ttorneys who previously worked at McKenna Long &am...anta office. The attorneys include Mark S. Lange, ...rporate department and Larry A. Slovensky, a par...lways pleased to welcome good lawyers back into th...look forward to the value Larry, Mark and Emily wi...
...nomyx, Inc. (Nasdaq: SNMX ) will release its fir... 7, 2009 before the opening of the U.S. financial ...call with a live Internet broadcast that will prov...uarter results on the same day at 11:00 a.m. Easte...ipate in the live conference call, U.S. residents ...
...OmniComm Systems, Inc. (OTC Bulletin Board: OMCM) ... clinical trials market today announced its result...09. , , Revenue for the first quarter of 2009 inc...o $1,012,000 in the same period of 2008. Gross pro...ended March 31, 2009 compared to 68.5% for the com...
Other Biology Technology:Three Attorneys Rejoin McKenna Long & Aldridge 2SENOMYX, INC. FIRST QUARTER 2009 EARNINGS CONFERENCE CALL SCHEDULED FOR MAY 7, 2009 2OmniComm Systems Announces 1st Quarter Results of Operations 2OmniComm Systems Announces 1st Quarter Results of Operations 3
Rabbit Anti-C/EBPalpha Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Kalinin Monoclonal Antibody, Unconjugated, Clone GB3 from Abcam
Rabbit Anti-Human VEZT Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human AADAC Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Biology Products: